News and Trends 31 Mar 2020 Swiss Biopharma Launches Second Cancer Antibody Deal with Japanese Pharma Giant …rights to develop and commercialize an immuno-oncology drug candidate for an unspecified indication using Numab’s multi-specific antibody platform, MATCH. Antibody-based therapies are becoming increasingly popular in oncology, with Merck’s approved… March 31, 2020 - 3 minutesmins - By David Kirk Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jan 2017 German Antibody for Cancer Diagnostics catches an Australian Eye …Wilex, in Germany, for the worldwide rights to Redectane, an antibody with diagnostic applications in renal cancer. The antibody, Rencarex (girentuximab), which binds to the CAIX antigen on clear cell… January 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 29 Aug 2019 HiFiBiO’s €60M Series C to Fund Cancer and Autoimmune Disease Antibody Drugs …also fuel the expansion of HiFiBiO’s antibody production technology, which is based on screening hundreds of single immune cells at a time for the most effective antibody drug candidate. HiFiBiO… August 29, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 30 Apr 2025 The future of NSCLC treatment: what’s in store for the therapeutic space? …candidates in the clinic trying to combat this inadequacy. And some of the candidates could be on their way beyond the clinic, as they are being evaluated in late-stage trials…. April 30, 2025 - 12 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 30 Jan 2017 The Shiniest Golden Vertex? 15 Great Biotechs in Cambridge …shown significant advantages over antibody-drug conjugates in preclinical models. Clinical trials for the first candidate are due to start in 2017. Acacia Pharma focuses on conditions caused by aggressive therapies,… January 30, 2017 - 8 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
Weekly Roundup 24 Nov 2023 Viva’s $210 million round; Merck grabs Caraway for $610 million; Genentech signs a deal with NVIDIA …an antibody that was discovered based on WuXi Bio’s integrated technology platforms, so that Myricx can develop an ADC using the antibody, to target solid tumors, through its NMT-1 platform…. November 24, 2023 - 14 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 21 Oct 2025 Seven of the top biotech companies to know about in South San Francisco …and other CNS disorders. Vistagen’s pipeline includes five clinical-stage product candidates, including its lead candidate fasedienol. Each candidate is an investigational agent belonging to a new class of drugs known… October 21, 2025 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 24 Oct 2024 Six biotech companies advancing multiple sclerosis therapies …debilitating disease. Table of contents Biogen Leading multiple sclerosis drug candidate of Biogen: BIIB091 Biogen is known for its pioneering work in the neuroscience field. It has been discovering and… October 24, 2024 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 27 May 2025 Interleukin therapeutics: 9 companies to follow in 2025 …for ANK-101 at the AACR Annual Meeting Ankyra Therapeutics is a biotech developing anchored immunotherapies aimed at enhancing the therapeutic window of cytokine-based treatments. The company’s lead candidate, ANK-101 (tolododekin… May 27, 2025 - 12 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 22 Dec 2022 10 biotech companies to watch in 2023 …candidates — called TCR-T cell therapies — are designed to tackle solid cancers. This is because they are genetically modified to express a custom version of a T-cell protein called… December 22, 2022 - 9 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 28 Oct 2025 The 11 most advanced microbiome players aiming for the gut …Adelaide, Australia Founded: 2018 Lead candidate: BB265 BiomeBank is a clinical-stage biotech developing microbiome therapeutics that restore gut microbial ecology. The company combines a first-generation donor-derived product with a second-generation, co-cultured… October 28, 2025 - 10 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 24 Jul 2025 Which biotech companies are gaining traction in genetic diseases? …to advance treatments for genetic diseases. Table of contents Actio Biosciences Headquarters: San Diego, U.S.A. Latest funding round: $66 million series B (June 2025) Lead candidates: ABS‑1230 for KCNT1-related epilepsy;… July 24, 2025 - 12 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email